Novo Nordisk A/S
NVO
$64.85
-$2.70-4.00%
NYSE
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
EPS (TTM)
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 12.25B | 10.51B | 9.82B | 9.52B | 9.51B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.25B | 10.51B | 9.82B | 9.52B | 9.51B |
| Cost of Revenue | 1.72B | 1.67B | 1.48B | 1.44B | 1.38B |
| Gross Profit | 10.52B | 8.84B | 8.34B | 8.07B | 8.13B |
| SG&A Expenses | 2.90B | 2.44B | 2.32B | 2.10B | 2.69B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -105.76M | 14.88M | -58.44M | 82.70M | -44.61M |
| Total Operating Expenses | 6.16B | 5.52B | 5.26B | 4.88B | 5.34B |
| Operating Income | 6.08B | 4.98B | 4.56B | 4.64B | 4.17B |
| Income Before Tax | 5.08B | 5.07B | 3.66B | 4.65B | 3.99B |
| Income Tax Expenses | 1.05B | 1.04B | 762.14M | 948.04M | 816.66M |
| Earnings from Continuing Operations | 4.03B | 4.02B | 2.89B | 3.70B | 3.17B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.03B | 4.02B | 2.89B | 3.70B | 3.17B |
| EBIT | 6.08B | 4.98B | 4.56B | 4.64B | 4.17B |
| EBITDA | 6.33B | 5.30B | 5.02B | 5.06B | 4.38B |
| EPS Basic | 0.91 | 0.90 | 0.65 | 0.83 | 0.71 |
| Normalized Basic EPS | 0.83 | 0.71 | 0.63 | 0.65 | 0.60 |
| EPS Diluted | 0.91 | 0.90 | 0.65 | 0.83 | 0.71 |
| Normalized Diluted EPS | 0.83 | 0.71 | 0.63 | 0.65 | 0.60 |
| Average Basic Shares Outstanding | 4.45B | 4.45B | 4.46B | 4.46B | 4.46B |
| Average Diluted Shares Outstanding | 4.46B | 4.46B | 4.47B | 4.47B | 4.48B |
| Dividend Per Share | 1.13 | 0.00 | 0.51 | -- | 0.92 |
| Payout Ratio | 0.00% | 57.08% | 0.00% | 112.40% | 0.00% |